Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Assets Average (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Assets Average for 12 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 23.94% to $1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 23.94% increase, with the full-year FY2025 number at $1.2 billion, up 36.79% from a year prior.
  • Assets Average was $1.3 billion for Q4 2025 at Madrigal Pharmaceuticals, up from $1.2 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.3 billion in Q4 2025 to a low of $187.5 million in Q3 2022.
  • A 5-year average of $606.7 million and a median of $333.2 million in 2021 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: plummeted 40.72% in 2022, then surged 302.1% in 2024.
  • Madrigal Pharmaceuticals' Assets Average stood at $289.0 million in 2021, then dropped by 9.83% to $260.6 million in 2022, then skyrocketed by 68.55% to $439.3 million in 2023, then skyrocketed by 140.81% to $1.1 billion in 2024, then rose by 23.94% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Assets Average are $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.0 billion (Q2 2025).